Prescription Medicines
Spolon Tab.
- Product Category
- Adrenocorticosteroids
- Active Ingredients
- Methylprednisolone
- Appearance
- A white, round tablet.
- Reimbursement Code
- 648103410
01 / 02
1. Composition and Strength
- Active ingredient: Methylprednisolone (USP)----4mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: calcium stearate, corn starch, sodium starch glycolate, purified water
2. Effectiveness
1. Endocrine disorders
Primary and secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first-line drug of choice; if necessary, synthetic corticosteroids may be used in combination with mineralocorticoids; it is especially important to use mineralcorticoids together in infancy), congenital adrenal abnormality hyperplasia, hypercalcemia accompanying cancer, and non-purulent thyroiditis.
2. Rheumatic disorders
As an adjuvant treatment for short-term administration to prevent acute progression or worsening, the following diseases: post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis including juvenile rheumatoid arthritis (low-dose maintenance therapy may be necessary in some cases), acute and subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, and ankylosing spondylitis.
3. Collagen disease
The following diseases are in exacerbation or require maintenance therapy: systemic lupus erythematosus (lupus nephritis), systemic dermatomyositis (polymyositis), and acute rheumatic carditis.
4. Skin disease
Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis, mycosis sarcoma
5. Allergic disease
The following diseases are serious or disabling allergic diseases that do not respond to general treatment: bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity reaction.
6. Eye diseases
The following severe acute and chronic allergic or inflammatory diseases related to the eyes and their appendages: herpes zoster, iritis and iridocyclitis, chorioretinitis, posterior diffuse uveitis and choroiditis, optic neuritis, sympathetic ophthalmitis, inflammation of the anterior chamber, allergic conjunctivitis, allergic pericorneal ulcer, keratitis.
7. Gastrointestinal diseases
The following diseases to overcome a critical crisis: ulcerative colitis, localized enteritis
8. Respiratory system disease
Symptomatic sarcoidosis, beryllium poisoning, fulminant or disseminated pulmonary tuberculosis (administered in combination with appropriate anti-tuberculosis chemotherapy drugs), Loeffler syndrome, aspiration pneumonia that is not cured by other methods.
9. Blood diseases
Acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, erythroblastopenia (red cell anemia), and congenital erythroid hypoplastic anemia
10. Malignant neoplastic disease
Palliative management of the following diseases: acute leukemia in children, leukemia and lymphoma in adults
11. Edematous disease
Inducing increased urination and alleviating proteinuria in idiopathic nephrotic syndrome without uremic symptoms or nephrotic syndrome due to lupus erythematosus
12. Nervous System Diseases
Acute exacerbation of multiple sclerosis
13. Others
Tuberculous meningitis (cases with subarachnoid blockage or concerns about blockage, administered in combination with appropriate anti-tuberculous chemotherapy), trichinellosis (cases with neurogenic or myocardial complications)
3. Dosage and dosage
1. The initial dosage may vary from 4 mg to 48 mg per day as methylprednisolone, depending on the symptoms of the specific disease. In general, low doses are sufficient for mild conditions, but high initial doses may be required in special patients. The initial dose should be maintained or adjusted until a satisfactory response is obtained. If there are no satisfactory clinical results after a reasonable period of time, administration should be discontinued and switched to another appropriate treatment. The dosage needs to be determined individually depending on the various diseases being treated and the patient's responsiveness. After an appropriate response appears, the appropriate maintenance dose should be determined by reducing the initial dose at appropriate intervals until the minimum dose that can maintain an appropriate clinical response is reached. Continuous monitoring of capacity is required. Circumstances in which dose adjustment may be necessary include the alleviation or worsening of the disease, the individual patient's drug responsiveness, and the effects on the patient of exposure to a stressful environment that does not directly affect the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to satisfy the patient's condition.
After long-term treatment, a slow decline is expected when the drug is discontinued.
2. Multiple sclerosis
The treatment of acute exacerbations of multiple sclerosis is effective by administering 200 mg of prednisolone daily for 1 week, followed by 80 mg of prednisolone every other day for 1 month (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone).
3. ADT (Alternate Day Therapy)
Alternate-day treatment is a method of administering twice the daily dose on one of the two days. The purpose of this method is to increase the effectiveness of corticosteroids in patients requiring long-term drug administration and to minimize adverse reactions such as pituitary-adrenal suppression, Cushingoid state, corticosteroid withdrawal symptoms, and growth inhibition in children. The theory of this treatment plan is based on two important premises:
1) The anti-inflammatory and therapeutic effects of corticosteroids last longer than their physical presence and metabolic effects.
2) Taking corticosteroids every other morning leads to the re-establishment of hypothalamus-pituitary-adrenal (HPA) activity, which is almost normal on days when corticosteroids are not administered. A brief summary of HPA physiology may help understand this theoretical interpretation. Free cortisol acts mainly through the hypothalamus, so a decrease in free cortisol stimulates the pituitary gland to increase production of adrenocorticotropic hormone (ACTH), while an increase in free cortisol inhibits ACTH secretion. Normally, the HPA system is characterized by a 24-hour activity rhythm. Serum levels of ACTH increase from a low level at 10 PM to a highest level at 6 AM. Increased levels of ACTH stimulate adrenocortical activity, resulting in peak increases in plasma cortisol between 2 and 8 am. This increase in cortisol reduces ACTH production and thus adrenal cortical synthesis. This causes plasma corticosteroids to drop gradually throughout the day, reaching minimal levels in the middle of the night. The 24-hour rhythm axis of the HPA is lost in Cushing's disease, which is a symptom of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thin skin that bruises easily, weakness and muscle loss, high blood pressure, latent diabetes, osteoporosis, and electrolyte imbalance. The same clinical symptoms of hyperadrenocorticism may appear during long-term corticosteroid therapy, which is typically administered in divided doses per day. If it has been shown, disruption of the diurnal rhythm due to maintenance of elevated corticosteroid levels during the night is likely to play an important role in the development of corticosteroid adverse reactions.
Avoidance of persistently elevated plasma levels, even for short periods of time, may be helpful in preventing adverse reactions. During typical pharmacological doses of corticosteroid therapy, ACTH production is suppressed along with the suppression of cortisol production by the adrenal cortex. Recovery time to normal HPA activity varies depending on dose and treatment period. During this period, patients are sensitive to any stressful environment. Although a single morning dose produces significantly less adrenal suppression than prednisolone (10 mg) divided into four doses every six hours, there is evidence that the slight suppressive effect on adrenal activity when administered at pharmacological doses continues into the next day. Additionally, a single dose of any corticosteroid produces suppression of the adrenal cortex for up to 2 days or more. Other corticosteroids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered short-acting (a single dose produces adrenocortical suppression for 1¼ to 1½ days) and therefore require treatment on alternate days.
The following points should be kept in mind when performing alternate-day treatment:
1) Basic principles and indications must be applied to corticosteroid therapy. The advantages of ADT should not encourage indiscriminate use of corticosteroids.
2) ADT is a treatment technique that should be basically planned for patients requiring long-term corticosteroid treatment.
3) For less severe disease with indications for corticosteroid therapy, ADT may be used initially. In more severe diseases, high-dose, divided-daily therapy will usually be required to initially control disease progression. Initial suppressive doses should be continued until a satisfactory clinical response is achieved, which is usually 4 to 10 days for many allergic and collagen diseases.
It is important to keep the initial suppressive dose period as short as possible, especially if continued use of the alternate-day regimen is intended. Once control is achieved, two cases are possible:
① Switch to ADT and gradually reduce the amount of corticosteroids given every other day.
② Depending on the control of disease progression, reduce the daily dose of corticosteroids to the minimum effective value as soon as possible and then change to an every other day schedule. Theoretically, process ① is more desirable.
4) Because of the advantages of ADT, this form of treatment is desirable for patients who have been taking daily corticosteroids for long periods of time (e.g. rheumatoid arthritis). Because these patients may already have a suppressed HPA axis, establishing ADT therapy may be difficult and not always successful. However, regular attempts to make changes are recommended. If difficulties are encountered, it may be advisable to administer three or even four times the dose every other day rather than simply doubling the daily dose. Once the patient is back under control, an attempt is made to reduce these doses to the lowest possible level.
5) As mentioned above, certain corticosteroids suppress adrenal function for a long time and are not recommended for alternate-day therapy (e.g. dexamethasone, betamethasone).
6) The maximum activity of the adrenal cortex is from 2 am to 8 am, and the lowest activity is from 4 pm to midnight. When administered during the time of peak activity (morning), exogenous corticosteroids suppress adrenocortical activity the least.
7) In the use of ADT, as in all treatment settings, it is important to individualize and provide appropriate treatment for each patient. Complete control of symptoms is not possible for all patients. Explanation of the benefits of ADT will help patients understand and tolerate the unstable symptoms that may occur during the second half of the corticosteroid-free day. If necessary, other symptomatic treatments may be added or increased during this period.
8) If an acute exacerbation occurs during the course of the disease, it may be necessary to divide the corticosteroid dose per day and return to a completely suppressive dose for control. Once controlled, the established alternate-day regimen can be retried.
9) Although many adverse reactions of corticosteroid therapy can be minimized with ADT, as in all treatment settings, physicians must carefully consider the ratio of treatment benefits and risks for each patient considered for corticosteroid treatment.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its ingredients
2) Patients with infections without effective antibacterial agents or systemic fungal infections (infections may worsen due to immune function suppression)
3) Patients with herpes simplex, shingles, or chickenpox
4) Patients receiving live or attenuated live vaccines
5) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) In principle, do not administer, but administer with caution to the following patients only when necessary.
① Patients with glaucoma (glaucoma may worsen due to increased intraocular pressure)
② Patients with tuberculosis disease or herpes simplex keratitis (symptoms may worsen due to immunosuppression)
③ Patients with posterior subcapsular cataracts (symptoms may worsen due to the influence of lens arrhythmia)
④ Patients with electrolyte abnormalities and high blood pressure (symptoms may worsen due to electrolyte metabolism)
⑤ Patients with thrombosis (thrombosis may worsen due to blood coagulation promotion effect)
⑥ Patients who recently underwent intestinal anastomosis (wound healing may be delayed)
⑦ Patients who have suffered an acute myocardial infarction (there are reports of cardiac rupture occurring)
⑧ Diverticulitis patient
⑨ Patients with peptic ulcers (symptoms may worsen as it reduces the protective effect of the digestive tract and interferes with tissue repair)
⑩ Patients with mental illness (symptoms may worsen due to effects on neurotransmitters in the cerebral insulator system)
⑪ Patients with severe osteoporosis (osteoporosis may worsen due to inhibition of bone formation, etc.)
2) Patients with infectious diseases (infections may worsen due to immune function suppression)
3) Diabetics (diabetes may worsen due to increased blood sugar levels due to gluconeogenesis)
4) Patients with osteoporosis (osteoporosis may worsen due to inhibition of bone formation, etc.)
5) Patients with renal failure or congestive heart failure (symptoms may worsen due to sodium retention)
6) Patients with hypothyroidism (there are reports that the blood half-life of corticosteroids is extended)
7) Fatty liver (fat deposition in the liver increases, which may worsen fatty liver disease)
8) Patients with fat embolism (there are reports that fat embolism occurred due to corticosteroid overdose)
9) Patients with myasthenia gravis (symptoms may temporarily worsen during initial use)
10) Elderly people
11) Epilepsy patients
12) Patients with ulcerative colitis (which may cause perforation, abscess, or other purulent infection)
13) Patients with a history of osteoporosis, high blood pressure, congestive heart failure, severe mood disorders, diabetes, tuberculosis, glaucoma, liver failure, renal failure, epilepsy, or peptic ulcer (the disease may worsen)
3. Adverse reactions
The following symptoms may appear, so observe thoroughly and take appropriate measures if these symptoms appear.
1) Body fluid/electrolytes: Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalemia, congestive heart failure, and hypertension may occur in susceptible patients.
2) Musculoskeletal system: Myasthenia gravis, aseptic necrosis of the distal end of the femur and humerus, steroid myopathy, loss of muscle parenchyma, pathological fractures of long bones, osteoporosis, spinal compression fractures, joint pain, and tendon rupture (especially Achilles tendon) may occur.
3) Digestive system: Increased ALT, AST, ALP, nausea, dry mouth, vomiting, stomach pain, loss of appetite, increased appetite, peptic ulcer with the possibility of perforation and bleeding, abdominal distension, pancreatitis, ulcerative esophagitis, diarrhea, etc. may occur.
4) Skin: Delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae and ecchymosis, inhibition of skin reaction, purpura, acne, hirsutism, hair loss, pigmentation, etc. may occur.
5) Mental/Nervous System: Increased intracranial pressure, convulsions, dizziness, headaches, insomnia, euphoria, and depression accompanied by papilledema (pseudotumor) may occur after treatment.
6) Endocrine system: Cushing's syndrome (lunar eye), menstrual abnormalities, growth inhibition in children, development of latent diabetes symptoms, secondary adrenal insufficiency and pituitary unresponsiveness (especially during stress such as trauma, surgery, disease, etc.), decreased glucose tolerance, increased requirement for insulin or oral hypoglycemic agents in diabetic patients, and suppression of adrenocorticotropic hormone secretion may occur.
7) Eyes: Continuous use may cause intraocular pressure, glaucoma, posterior subcapsular cataracts, and secondary eye infections due to fungi or viruses, so regular examinations are recommended. Retinal disorders and exophthalmos may occur due to central serous chorioretinopathy.
8) Lipid/protein metabolism: Negative nitrogen balance may occur due to protein catabolism.
9) Immune system: Immune system disorders, allergic reactions when used intravenously, and in rare cases even shock may occur.
10) Others: The following adverse reactions have been reported during oral and parenteral administration in relation to corticosteroid therapy.
- Hives, other allergic reactions, anaphylactic reactions, hypersensitivity reactions
4. Generalism
1) Secondary adrenal cortical insufficiency may occur during long-term administration and may continue for several months after discontinuation of administration. If corticosteroids are suddenly stopped after long-term administration, acute adrenal failure, sometimes fever, headache, loss of appetite, weakness, muscle pain, joint pain, shock symptoms, etc. may occur, so be especially careful to gradually reduce the dose. If withdrawal symptoms appear, immediately re-administer or increase the dose. If stress such as trauma, surgery, or infection occurs during long-term administration, the dosage should be temporarily increased, and if administration is stopped after long-term administration, it must be temporarily re-administered. Because mineralocorticoid secretion may be impaired, it is advisable to use saline or mineralocorticoids together.
2) During long-term treatment, treatment should be started after considering the risk. Since adverse reactions are related to the dose and period of administration, the minimum effective dose should be administered for as short a period of time as possible, and administration once a day in the morning or every other day is recommended.
3) Patients (children) receiving immunosuppressants are more susceptible to infection than healthy people (children). For example, chickenpox or measles can cause more serious or even fatal outcomes in patients taking the immunosuppressant corticosteroids. Adults and children who have never suffered from these diseases should be especially careful to avoid exposure to them. If exposed to chickenpox, preventive treatment such as varicella-zoster immune globulin (VZIG) is required within 3 to 10 days, and if exposed to measles, immunoglobulin (IG) is required. If chickenpox occurs, the use of antiviral drugs is considered.
4) Patients receiving corticosteroid therapy should not receive live vaccines, and due to the possibility of neurological complications and lack of antibody response, patients receiving corticosteroids in particular at high doses should not receive any other vaccinations.
5) When corticosteroids are administered, the symptoms of infection can sometimes be suppressed and another infection may occur during use. During corticosteroid administration, the ability to localize infection and resistance may be reduced.
6) Administration of this drug to patients with active tuberculosis is limited to fulminant and disseminated tuberculosis and should be administered in combination with an appropriate anti-tuberculosis treatment.
7) When corticosteroids are administered to patients with latent tuberculosis or those with a positive tuberculin reaction, close observation is required as tuberculosis may be reactivated, and in case of long-term use, prophylactic chemotherapy must be administered.
8) In clinical trials, corticosteroids have been shown to be effective in quickly alleviating acute exacerbations of multiple sclerosis, but they cannot be considered a fundamental treatment.
9) When hydrocortisone or cortisone is used in an average or higher dose, it may cause increased blood pressure, salt and water retention, and increased potassium excretion. However, there is no risk of such effects due to synthetic derivatives except in case of excessive administration. Salt restriction and potassium supplementation may be necessary when eating food. All corticosteroids increase calcium excretion.
10) During post-marketing use, tumor lysis syndrome (TLS) was reported in patients with malignant tumors, including blood cancers and solid tumors, after systemic corticosteroids were administered alone or in combination with other chemotherapy agents. Patients at high risk of tumor lysis syndrome have a high tumor proliferation rate, high tumor burden, and high sensitivity to cytotoxic anticancer drugs, so they must be carefully monitored and appropriate measures taken.
11) In particular, if you are infected with chickenpox or measles while taking this medicine, it may lead to a fatal outcome, so the following precautions are required.
① Before administering this medicine, check the history of chickenpox or measles and whether or not you have been vaccinated.
② For patients without a history of chickenpox or measles, provide sufficient consideration and observation to prevent infection with chickenpox or measles as much as possible. If infection is suspected or infected, immediately receive a medical examination, receive guidance, and take appropriate measures.
③ Be aware that even patients with a history of chickenpox or measles and who have been vaccinated may develop chickenpox or measles while taking this medicine.
5. Interaction
1) Do not co-administer with drugs that can cause polymorphic ventricular tachycardia (astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, vincarmine, sultopride).
2) Concomitant use with antiarrhythmic drugs that can cause polymorphic ventricular tachycardia (amiodarone, disopyramide, quinidine, sotalol) can cause bradycardia, QT interval prolongation, hypokalemia, etc., which can cause arrhythmia, so administer with caution and discontinue antiarrhythmic drug administration if ventricular tachycardia occurs.
3) The effect of this drug may be reduced by co-administration with barbiturates (phenobarbital), phenytoin, rifampicin, carbamazepine, primidone, aminoglutethimide, and rifabutin, so be careful about the dosage when co-administered.
4) Co-administration with non-steroidal anti-inflammatory drugs may increase the risk of gastrointestinal ulcers, and co-administration with aspirin may increase the renal clearance of aspirin, reducing the blood concentration of salicylate or increasing salicylate toxicity when discontinuing this drug, so be careful with the dosage. Caution should be exercised when coadministering this drug and aspirin, especially in patients with hypoprothrombinemia.
5) In the case of anticoagulants and hypoglycemic agents, their effects may be weakened by co-administration with corticosteroids, so dose adjustment is necessary.
6) Hypokalemia may occur due to concomitant use of diuretics (excluding potassium-sparing diuretics), amphotericin B, carbenozolone, and laxatives, so frequently check blood potassium concentration and pay attention to dosage when administered together.
7) When co-administered with digitalis glycosides, toxicity related to arrhythmia and hypokalemia may increase, so check the potassium concentration in the blood and, in some cases, conduct an electrocardiogram.
8) When administered in combination with isoniazid, the blood concentration of isoniazid decreases, so dosage adjustment is necessary.
9) Since antacids interfere with the gastrointestinal absorption of glucocorticoids, the interval between administration should be at least 2 hours.
10) When administered in combination with antihypertensive drugs, the blood pressure lowering effect may be reduced (there is a risk of water retention due to increased sodium).
11) When administered in combination with alpha interferon, the activity of interferon may be inhibited.
12) There have been reports that convulsions occurred due to increased blood concentration of cyclosporine when administered in combination with cyclosporine, so be careful about the dosage when administered together.
13) Ketoconazole, erythromycin, troleandomycin, and estrogen may increase the action of this drug, so be careful about dose adjustment when administered together.
14) When combined with non-depolarizing muscle relaxants (pancuronium bromide, etc.), the muscle relaxant effect may be decreased or increased, so be careful about the dosage when administered together.
15) The risk of blood changes may increase due to combined use with ACE inhibitors.
16) Combination use with chloroquine and hydroxychloroquine may increase the risk of myopathy and cardiomyopathy.
17) Combined use with somatropin may reduce the effect of somatropin.
6. Administration to pregnant and lactating women
1) Teratogenic effects have been reported in animal experiments, and it can cause fetal growth retardation, increase the risk of cleft lip, and affect fetal brain growth and development. It can also cause adrenal insufficiency in newborns born to mothers who administered corticosteroids during pregnancy. Therefore, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) Since corticosteroids may pass into breast milk, breast-feeding should be discontinued while taking this medicine.
7. Administration to children
1) Since dose-related growth retardation may occur irreversibly in children and adolescents, when administering corticosteroids to children, the minimum dose should be administered and growth and growth should be carefully observed.
2) In case of long-term administration, symptoms of intracranial hypertension may occur.
8. Administration to elderly people
When administered long-term to the elderly, adverse reactions such as infection, diabetes, osteoporosis, high blood pressure, posterior subcapsular cataract, and glaucoma are likely to occur, so observe carefully and administer carefully.
9. Other
1) Hypokalemia may occur due to combined use with β2-agonists.
2) There are reports from foreign countries that the effectiveness of killed and inactivated vaccines has been reduced.
3) Since the skin test reaction may be suppressed by the administration of corticosteroids, be careful when performing a skin test while taking this drug.
4) There are reports of pseudocephalic tumors appearing in foreign countries.
5) Kaposi's sarcoma has been reported in patients receiving corticosteroids.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 200 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Methylprednisolone (USP)----4mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: calcium stearate, corn starch, sodium starch glycolate, purified water
2. Effectiveness
1. Endocrine disorders
Primary and secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first-line drug of choice; if necessary, synthetic corticosteroids may be used in combination with mineralocorticoids; it is especially important to use mineralcorticoids together in infancy), congenital adrenal abnormality hyperplasia, hypercalcemia accompanying cancer, and non-purulent thyroiditis.
2. Rheumatic disorders
As an adjuvant treatment for short-term administration to prevent acute progression or worsening, the following diseases: post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis including juvenile rheumatoid arthritis (low-dose maintenance therapy may be necessary in some cases), acute and subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, and ankylosing spondylitis.
3. Collagen disease
The following diseases are in exacerbation or require maintenance therapy: systemic lupus erythematosus (lupus nephritis), systemic dermatomyositis (polymyositis), and acute rheumatic carditis.
4. Skin disease
Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis, mycosis sarcoma
5. Allergic disease
The following diseases are serious or disabling allergic diseases that do not respond to general treatment: bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity reaction.
6. Eye diseases
The following severe acute and chronic allergic or inflammatory diseases related to the eyes and their appendages: herpes zoster, iritis and iridocyclitis, chorioretinitis, posterior diffuse uveitis and choroiditis, optic neuritis, sympathetic ophthalmitis, inflammation of the anterior chamber, allergic conjunctivitis, allergic pericorneal ulcer, keratitis.
7. Gastrointestinal diseases
The following diseases to overcome a critical crisis: ulcerative colitis, localized enteritis
8. Respiratory system disease
Symptomatic sarcoidosis, beryllium poisoning, fulminant or disseminated pulmonary tuberculosis (administered in combination with appropriate anti-tuberculosis chemotherapy drugs), Loeffler syndrome, aspiration pneumonia that is not cured by other methods.
9. Blood diseases
Acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, erythroblastopenia (red cell anemia), and congenital erythroid hypoplastic anemia
10. Malignant neoplastic disease
Palliative management of the following diseases: acute leukemia in children, leukemia and lymphoma in adults
11. Edematous disease
Inducing increased urination and alleviating proteinuria in idiopathic nephrotic syndrome without uremic symptoms or nephrotic syndrome due to lupus erythematosus
12. Nervous System Diseases
Acute exacerbation of multiple sclerosis
13. Others
Tuberculous meningitis (cases with subarachnoid blockage or concerns about blockage, administered in combination with appropriate anti-tuberculous chemotherapy), trichinellosis (cases with neurogenic or myocardial complications)
3. Dosage and dosage
1. The initial dosage may vary from 4 mg to 48 mg per day as methylprednisolone, depending on the symptoms of the specific disease. In general, low doses are sufficient for mild conditions, but high initial doses may be required in special patients. The initial dose should be maintained or adjusted until a satisfactory response is obtained. If there are no satisfactory clinical results after a reasonable period of time, administration should be discontinued and switched to another appropriate treatment. The dosage needs to be determined individually depending on the various diseases being treated and the patient's responsiveness. After an appropriate response appears, the appropriate maintenance dose should be determined by reducing the initial dose at appropriate intervals until the minimum dose that can maintain an appropriate clinical response is reached. Continuous monitoring of capacity is required. Circumstances in which dose adjustment may be necessary include the alleviation or worsening of the disease, the individual patient's drug responsiveness, and the effects on the patient of exposure to a stressful environment that does not directly affect the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to satisfy the patient's condition.
After long-term treatment, a slow decline is expected when the drug is discontinued.
2. Multiple sclerosis
The treatment of acute exacerbations of multiple sclerosis is effective by administering 200 mg of prednisolone daily for 1 week, followed by 80 mg of prednisolone every other day for 1 month (4 mg of methylprednisolone is equivalent to 5 mg of prednisolone).
3. ADT (Alternate Day Therapy)
Alternate-day treatment is a method of administering twice the daily dose on one of the two days. The purpose of this method is to increase the effectiveness of corticosteroids in patients requiring long-term drug administration and to minimize adverse reactions such as pituitary-adrenal suppression, Cushingoid state, corticosteroid withdrawal symptoms, and growth inhibition in children. The theory of this treatment plan is based on two important premises:
1) The anti-inflammatory and therapeutic effects of corticosteroids last longer than their physical presence and metabolic effects.
2) Taking corticosteroids every other morning leads to the re-establishment of hypothalamus-pituitary-adrenal (HPA) activity, which is almost normal on days when corticosteroids are not administered. A brief summary of HPA physiology may help understand this theoretical interpretation. Free cortisol acts mainly through the hypothalamus, so a decrease in free cortisol stimulates the pituitary gland to increase production of adrenocorticotropic hormone (ACTH), while an increase in free cortisol inhibits ACTH secretion. Normally, the HPA system is characterized by a 24-hour activity rhythm. Serum levels of ACTH increase from a low level at 10 PM to a highest level at 6 AM. Increased levels of ACTH stimulate adrenocortical activity, resulting in peak increases in plasma cortisol between 2 and 8 am. This increase in cortisol reduces ACTH production and thus adrenal cortical synthesis. This causes plasma corticosteroids to drop gradually throughout the day, reaching minimal levels in the middle of the night. The 24-hour rhythm axis of the HPA is lost in Cushing's disease, which is a symptom of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thin skin that bruises easily, weakness and muscle loss, high blood pressure, latent diabetes, osteoporosis, and electrolyte imbalance. The same clinical symptoms of hyperadrenocorticism may appear during long-term corticosteroid therapy, which is typically administered in divided doses per day. If it has been shown, disruption of the diurnal rhythm due to maintenance of elevated corticosteroid levels during the night is likely to play an important role in the development of corticosteroid adverse reactions.
Avoidance of persistently elevated plasma levels, even for short periods of time, may be helpful in preventing adverse reactions. During typical pharmacological doses of corticosteroid therapy, ACTH production is suppressed along with the suppression of cortisol production by the adrenal cortex. Recovery time to normal HPA activity varies depending on dose and treatment period. During this period, patients are sensitive to any stressful environment. Although a single morning dose produces significantly less adrenal suppression than prednisolone (10 mg) divided into four doses every six hours, there is evidence that the slight suppressive effect on adrenal activity when administered at pharmacological doses continues into the next day. Additionally, a single dose of any corticosteroid produces suppression of the adrenal cortex for up to 2 days or more. Other corticosteroids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered short-acting (a single dose produces adrenocortical suppression for 1¼ to 1½ days) and therefore require treatment on alternate days.
The following points should be kept in mind when performing alternate-day treatment:
1) Basic principles and indications must be applied to corticosteroid therapy. The advantages of ADT should not encourage indiscriminate use of corticosteroids.
2) ADT is a treatment technique that should be basically planned for patients requiring long-term corticosteroid treatment.
3) For less severe disease with indications for corticosteroid therapy, ADT may be used initially. In more severe diseases, high-dose, divided-daily therapy will usually be required to initially control disease progression. Initial suppressive doses should be continued until a satisfactory clinical response is achieved, which is usually 4 to 10 days for many allergic and collagen diseases.
It is important to keep the initial suppressive dose period as short as possible, especially if continued use of the alternate-day regimen is intended. Once control is achieved, two cases are possible:
① Switch to ADT and gradually reduce the amount of corticosteroids given every other day.
② Depending on the control of disease progression, reduce the daily dose of corticosteroids to the minimum effective value as soon as possible and then change to an every other day schedule. Theoretically, process ① is more desirable.
4) Because of the advantages of ADT, this form of treatment is desirable for patients who have been taking daily corticosteroids for long periods of time (e.g. rheumatoid arthritis). Because these patients may already have a suppressed HPA axis, establishing ADT therapy may be difficult and not always successful. However, regular attempts to make changes are recommended. If difficulties are encountered, it may be advisable to administer three or even four times the dose every other day rather than simply doubling the daily dose. Once the patient is back under control, an attempt is made to reduce these doses to the lowest possible level.
5) As mentioned above, certain corticosteroids suppress adrenal function for a long time and are not recommended for alternate-day therapy (e.g. dexamethasone, betamethasone).
6) The maximum activity of the adrenal cortex is from 2 am to 8 am, and the lowest activity is from 4 pm to midnight. When administered during the time of peak activity (morning), exogenous corticosteroids suppress adrenocortical activity the least.
7) In the use of ADT, as in all treatment settings, it is important to individualize and provide appropriate treatment for each patient. Complete control of symptoms is not possible for all patients. Explanation of the benefits of ADT will help patients understand and tolerate the unstable symptoms that may occur during the second half of the corticosteroid-free day. If necessary, other symptomatic treatments may be added or increased during this period.
8) If an acute exacerbation occurs during the course of the disease, it may be necessary to divide the corticosteroid dose per day and return to a completely suppressive dose for control. Once controlled, the established alternate-day regimen can be retried.
9) Although many adverse reactions of corticosteroid therapy can be minimized with ADT, as in all treatment settings, physicians must carefully consider the ratio of treatment benefits and risks for each patient considered for corticosteroid treatment.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its ingredients
2) Patients with infections without effective antibacterial agents or systemic fungal infections (infections may worsen due to immune function suppression)
3) Patients with herpes simplex, shingles, or chickenpox
4) Patients receiving live or attenuated live vaccines
5) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) In principle, do not administer, but administer with caution to the following patients only when necessary.
① Patients with glaucoma (glaucoma may worsen due to increased intraocular pressure)
② Patients with tuberculosis disease or herpes simplex keratitis (symptoms may worsen due to immunosuppression)
③ Patients with posterior subcapsular cataracts (symptoms may worsen due to the influence of lens arrhythmia)
④ Patients with electrolyte abnormalities and high blood pressure (symptoms may worsen due to electrolyte metabolism)
⑤ Patients with thrombosis (thrombosis may worsen due to blood coagulation promotion effect)
⑥ Patients who recently underwent intestinal anastomosis (wound healing may be delayed)
⑦ Patients who have suffered an acute myocardial infarction (there are reports of cardiac rupture occurring)
⑧ Diverticulitis patient
⑨ Patients with peptic ulcers (symptoms may worsen as it reduces the protective effect of the digestive tract and interferes with tissue repair)
⑩ Patients with mental illness (symptoms may worsen due to effects on neurotransmitters in the cerebral insulator system)
⑪ Patients with severe osteoporosis (osteoporosis may worsen due to inhibition of bone formation, etc.)
2) Patients with infectious diseases (infections may worsen due to immune function suppression)
3) Diabetics (diabetes may worsen due to increased blood sugar levels due to gluconeogenesis)
4) Patients with osteoporosis (osteoporosis may worsen due to inhibition of bone formation, etc.)
5) Patients with renal failure or congestive heart failure (symptoms may worsen due to sodium retention)
6) Patients with hypothyroidism (there are reports that the blood half-life of corticosteroids is extended)
7) Fatty liver (fat deposition in the liver increases, which may worsen fatty liver disease)
8) Patients with fat embolism (there are reports that fat embolism occurred due to corticosteroid overdose)
9) Patients with myasthenia gravis (symptoms may temporarily worsen during initial use)
10) Elderly people
11) Epilepsy patients
12) Patients with ulcerative colitis (which may cause perforation, abscess, or other purulent infection)
13) Patients with a history of osteoporosis, high blood pressure, congestive heart failure, severe mood disorders, diabetes, tuberculosis, glaucoma, liver failure, renal failure, epilepsy, or peptic ulcer (the disease may worsen)
3. Adverse reactions
The following symptoms may appear, so observe thoroughly and take appropriate measures if these symptoms appear.
1) Body fluid/electrolytes: Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalemia, congestive heart failure, and hypertension may occur in susceptible patients.
2) Musculoskeletal system: Myasthenia gravis, aseptic necrosis of the distal end of the femur and humerus, steroid myopathy, loss of muscle parenchyma, pathological fractures of long bones, osteoporosis, spinal compression fractures, joint pain, and tendon rupture (especially Achilles tendon) may occur.
3) Digestive system: Increased ALT, AST, ALP, nausea, dry mouth, vomiting, stomach pain, loss of appetite, increased appetite, peptic ulcer with the possibility of perforation and bleeding, abdominal distension, pancreatitis, ulcerative esophagitis, diarrhea, etc. may occur.
4) Skin: Delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae and ecchymosis, inhibition of skin reaction, purpura, acne, hirsutism, hair loss, pigmentation, etc. may occur.
5) Mental/Nervous System: Increased intracranial pressure, convulsions, dizziness, headaches, insomnia, euphoria, and depression accompanied by papilledema (pseudotumor) may occur after treatment.
6) Endocrine system: Cushing's syndrome (lunar eye), menstrual abnormalities, growth inhibition in children, development of latent diabetes symptoms, secondary adrenal insufficiency and pituitary unresponsiveness (especially during stress such as trauma, surgery, disease, etc.), decreased glucose tolerance, increased requirement for insulin or oral hypoglycemic agents in diabetic patients, and suppression of adrenocorticotropic hormone secretion may occur.
7) Eyes: Continuous use may cause intraocular pressure, glaucoma, posterior subcapsular cataracts, and secondary eye infections due to fungi or viruses, so regular examinations are recommended. Retinal disorders and exophthalmos may occur due to central serous chorioretinopathy.
8) Lipid/protein metabolism: Negative nitrogen balance may occur due to protein catabolism.
9) Immune system: Immune system disorders, allergic reactions when used intravenously, and in rare cases even shock may occur.
10) Others: The following adverse reactions have been reported during oral and parenteral administration in relation to corticosteroid therapy.
- Hives, other allergic reactions, anaphylactic reactions, hypersensitivity reactions
4. Generalism
1) Secondary adrenal cortical insufficiency may occur during long-term administration and may continue for several months after discontinuation of administration. If corticosteroids are suddenly stopped after long-term administration, acute adrenal failure, sometimes fever, headache, loss of appetite, weakness, muscle pain, joint pain, shock symptoms, etc. may occur, so be especially careful to gradually reduce the dose. If withdrawal symptoms appear, immediately re-administer or increase the dose. If stress such as trauma, surgery, or infection occurs during long-term administration, the dosage should be temporarily increased, and if administration is stopped after long-term administration, it must be temporarily re-administered. Because mineralocorticoid secretion may be impaired, it is advisable to use saline or mineralocorticoids together.
2) During long-term treatment, treatment should be started after considering the risk. Since adverse reactions are related to the dose and period of administration, the minimum effective dose should be administered for as short a period of time as possible, and administration once a day in the morning or every other day is recommended.
3) Patients (children) receiving immunosuppressants are more susceptible to infection than healthy people (children). For example, chickenpox or measles can cause more serious or even fatal outcomes in patients taking the immunosuppressant corticosteroids. Adults and children who have never suffered from these diseases should be especially careful to avoid exposure to them. If exposed to chickenpox, preventive treatment such as varicella-zoster immune globulin (VZIG) is required within 3 to 10 days, and if exposed to measles, immunoglobulin (IG) is required. If chickenpox occurs, the use of antiviral drugs is considered.
4) Patients receiving corticosteroid therapy should not receive live vaccines, and due to the possibility of neurological complications and lack of antibody response, patients receiving corticosteroids in particular at high doses should not receive any other vaccinations.
5) When corticosteroids are administered, the symptoms of infection can sometimes be suppressed and another infection may occur during use. During corticosteroid administration, the ability to localize infection and resistance may be reduced.
6) Administration of this drug to patients with active tuberculosis is limited to fulminant and disseminated tuberculosis and should be administered in combination with an appropriate anti-tuberculosis treatment.
7) When corticosteroids are administered to patients with latent tuberculosis or those with a positive tuberculin reaction, close observation is required as tuberculosis may be reactivated, and in case of long-term use, prophylactic chemotherapy must be administered.
8) In clinical trials, corticosteroids have been shown to be effective in quickly alleviating acute exacerbations of multiple sclerosis, but they cannot be considered a fundamental treatment.
9) When hydrocortisone or cortisone is used in an average or higher dose, it may cause increased blood pressure, salt and water retention, and increased potassium excretion. However, there is no risk of such effects due to synthetic derivatives except in case of excessive administration. Salt restriction and potassium supplementation may be necessary when eating food. All corticosteroids increase calcium excretion.
10) During post-marketing use, tumor lysis syndrome (TLS) was reported in patients with malignant tumors, including blood cancers and solid tumors, after systemic corticosteroids were administered alone or in combination with other chemotherapy agents. Patients at high risk of tumor lysis syndrome have a high tumor proliferation rate, high tumor burden, and high sensitivity to cytotoxic anticancer drugs, so they must be carefully monitored and appropriate measures taken.
11) In particular, if you are infected with chickenpox or measles while taking this medicine, it may lead to a fatal outcome, so the following precautions are required.
① Before administering this medicine, check the history of chickenpox or measles and whether or not you have been vaccinated.
② For patients without a history of chickenpox or measles, provide sufficient consideration and observation to prevent infection with chickenpox or measles as much as possible. If infection is suspected or infected, immediately receive a medical examination, receive guidance, and take appropriate measures.
③ Be aware that even patients with a history of chickenpox or measles and who have been vaccinated may develop chickenpox or measles while taking this medicine.
5. Interaction
1) Do not co-administer with drugs that can cause polymorphic ventricular tachycardia (astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, vincarmine, sultopride).
2) Concomitant use with antiarrhythmic drugs that can cause polymorphic ventricular tachycardia (amiodarone, disopyramide, quinidine, sotalol) can cause bradycardia, QT interval prolongation, hypokalemia, etc., which can cause arrhythmia, so administer with caution and discontinue antiarrhythmic drug administration if ventricular tachycardia occurs.
3) The effect of this drug may be reduced by co-administration with barbiturates (phenobarbital), phenytoin, rifampicin, carbamazepine, primidone, aminoglutethimide, and rifabutin, so be careful about the dosage when co-administered.
4) Co-administration with non-steroidal anti-inflammatory drugs may increase the risk of gastrointestinal ulcers, and co-administration with aspirin may increase the renal clearance of aspirin, reducing the blood concentration of salicylate or increasing salicylate toxicity when discontinuing this drug, so be careful with the dosage. Caution should be exercised when coadministering this drug and aspirin, especially in patients with hypoprothrombinemia.
5) In the case of anticoagulants and hypoglycemic agents, their effects may be weakened by co-administration with corticosteroids, so dose adjustment is necessary.
6) Hypokalemia may occur due to concomitant use of diuretics (excluding potassium-sparing diuretics), amphotericin B, carbenozolone, and laxatives, so frequently check blood potassium concentration and pay attention to dosage when administered together.
7) When co-administered with digitalis glycosides, toxicity related to arrhythmia and hypokalemia may increase, so check the potassium concentration in the blood and, in some cases, conduct an electrocardiogram.
8) When administered in combination with isoniazid, the blood concentration of isoniazid decreases, so dosage adjustment is necessary.
9) Since antacids interfere with the gastrointestinal absorption of glucocorticoids, the interval between administration should be at least 2 hours.
10) When administered in combination with antihypertensive drugs, the blood pressure lowering effect may be reduced (there is a risk of water retention due to increased sodium).
11) When administered in combination with alpha interferon, the activity of interferon may be inhibited.
12) There have been reports that convulsions occurred due to increased blood concentration of cyclosporine when administered in combination with cyclosporine, so be careful about the dosage when administered together.
13) Ketoconazole, erythromycin, troleandomycin, and estrogen may increase the action of this drug, so be careful about dose adjustment when administered together.
14) When combined with non-depolarizing muscle relaxants (pancuronium bromide, etc.), the muscle relaxant effect may be decreased or increased, so be careful about the dosage when administered together.
15) The risk of blood changes may increase due to combined use with ACE inhibitors.
16) Combination use with chloroquine and hydroxychloroquine may increase the risk of myopathy and cardiomyopathy.
17) Combined use with somatropin may reduce the effect of somatropin.
6. Administration to pregnant and lactating women
1) Teratogenic effects have been reported in animal experiments, and it can cause fetal growth retardation, increase the risk of cleft lip, and affect fetal brain growth and development. It can also cause adrenal insufficiency in newborns born to mothers who administered corticosteroids during pregnancy. Therefore, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) Since corticosteroids may pass into breast milk, breast-feeding should be discontinued while taking this medicine.
7. Administration to children
1) Since dose-related growth retardation may occur irreversibly in children and adolescents, when administering corticosteroids to children, the minimum dose should be administered and growth and growth should be carefully observed.
2) In case of long-term administration, symptoms of intracranial hypertension may occur.
8. Administration to elderly people
When administered long-term to the elderly, adverse reactions such as infection, diabetes, osteoporosis, high blood pressure, posterior subcapsular cataract, and glaucoma are likely to occur, so observe carefully and administer carefully.
9. Other
1) Hypokalemia may occur due to combined use with β2-agonists.
2) There are reports from foreign countries that the effectiveness of killed and inactivated vaccines has been reduced.
3) Since the skin test reaction may be suppressed by the administration of corticosteroids, be careful when performing a skin test while taking this drug.
4) There are reports of pseudocephalic tumors appearing in foreign countries.
5) Kaposi's sarcoma has been reported in patients receiving corticosteroids.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 200 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 3items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 3 | Spolon Tab. | Precautions for use | 2026.03.09 | PDF0051_201403152_ Spollon tablet_Precautions for use.pdf |
| 2 | Spolon Tab. | Precautions for use | 2025.05.07 | PDFSpollon tablet_201403152_Precautions for use.pdf |
| 1 | Spolon Tab. | Precautions for use | 2024.06.07 | PDFSpallonjeong_Permit change order (draft) (precautions for use).pdf |